Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO timing trial for chemotherapy-induced thrombocytopenia in bone and soft tissue sarcoma
ChiCTR1900022667Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- May 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT) (2 arms), sponsored by Union Hospital. Primary endpoint: Incidence of grade III/IV thrombocytopenia. Planned start May 2019; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR1900022667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022667.